liver transplantation. Liver transplant status
Conditions
Interventions
Intervention 1: Intervention group: Intervention group: Patients will receive 10mg (Gloripa) of empagliflozin oral once daily for six months with standard treatments. Intervention 2: Intervention grou
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: patients with liver transplantation aged 18 to 80 consented patients
Exclusion criteria
Exclusion criteria: Pregnancy Lactation kidney failure heart failure contraindications of empagliflozin or dapagliflozin systolic blood pressure less than 100 or more than 180 mm Hg Autoinflammatory diseases Malignancy Diabetes mellitus
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Acute organ rejection. Timepoint: before intervention, second week,4th week, 8th week, 12th week and 16th week after intervention. Method of measurement: biopsy.;Survival of transplanted tissue. Timepoint: at baseline, the third month and the sixth month after the intervention. Method of measurement: clinical assessment. | — |
Secondary
| Measure | Time frame |
|---|---|
| Effect of empagliflozin and dapagliflozin on the incidence of new diabetes mellitus following liver transplantation. Timepoint: at baseline, the third month and the sixth month after the intervention. Method of measurement: Measurement of hemoglobin A1C, fasting blood sugar and two-hour blood sugar. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr Afshin Gharekhani
Tabriz University of Medical Sciences
Outcome results
None listed